Table 4 Distribution of exclusion criteria (GG, number of cores, cancer core infiltration) among patients who were Active Surveillance ineligible when MRI-targeted biopsy was added to systematic biopsy.

From: Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study

Guideline

Excluded patients by any AS criterion (%)

Criterion for exclusion (% of all excluded patients per guideline)

Max. GG only

Max. cores only

Max. infiltration only

Max. GG & cores

Max. GG & infiltration

Max. cores & infiltration

Max. GG & cores & infiltration

NCCS

5.3

3.2

48.4

0

22.6

0

12.9

12.9

CCO

10.3

8.3

38.3

1.7

21.7

0

10.0

20.0

FCCG & DUA

11.0

7.8

51.6

-

40.6

-

-

-

GSU

10.1

8.5

39.0

0.0

22.0

0.0

10.2

20.3

I+CS low risk

6.8

57.5

-

0

-

42.5

-

-

I+CS high risk

6.8

52.5

-

0

-

47.5

-

-

NCCN very low risk

4.6

3.7

48.1

0

22.2

0

14.8

11.1

NCCN favourable intermediate risk

7.2

57.1

-

0

-

42.9

-

-

AUA very low risk

3.8

36.4

0

18.2

4.5

22.7

9.1

9.1

PCFA low risk, KCE, EAU low risk, ESMO low risk, NICE low risk, NICE intermediate risk, NCCN low risk, AUA low risk, AUA favourable intermediate risk

4.1–11.4

100

-

-

-

-

-

-

  1. AS active surveillance, GG gleason grade.
  2. AUA American Urological Association [2], CCO Cancer Care Ontario [12], DUA Dutch Urological Association [13], EAU European Association of Urology [6], ESMO European Society for Medical Oncology [14], FCCG The Finnish Medical Society Duodecim [15], GSU German Society of Urology [5], I+CS Aragon Institute of Health Sciences [16], KCE Belgian Healthcare Knowledge Centre [17], NICE National Institute for Health and Clinical Excellence [8], NCCN The National Comprehensive Cancer Network [18], NCCS National Cancer Centre Singapore [19], PCFA Prostate Cancer Foundation of Australia [20].
Back to article page